{"prompt": "['Product: MK-3475', '74', 'Protocol/Amendment No.: 604-09', 'clinically indicated. Adverse experiences will be graded and recorded throughout the study', 'and during the follow-up period according to NCI CTCAE 4.0 (see Section 12.4). Toxicities', 'will be characterized in terms including seriousness, causality, toxicity grading, and action', 'taken with regard to trial treatment.', 'Please refer to Section 7.2 for detailed information regarding the assessment and recording of', 'AEs.', '7.1.2.2 Physical Examination', '7.1.2.2.1 Full Physical Examination', 'The investigator or qualified designee will perform a full physical examination during the', 'screening period before the Initial Treatment Phase, and on Cycle 1, Day 1 of the Second', 'Course Treatment Phase. Clinically significant abnormal findings should be recorded as', 'medical history. The time points for full physical examination are described in the Trial Flow', 'Chart (Section 6). After the first dose of trial treatment new clinically significant abnormal', 'findings should be recorded as AEs.', '7.1.2.2.2 Directed Physical Examination', 'For cycles/visits that do not require a full physical examination per the Trial Flow Chart', '(Section 6), the investigator or qualified designee will perform a directed physical', 'examination as clinically indicated prior to trial treatment administration and at other times', 'according to the Trial Flow Chart (Section 6). New clinically significant abnormal findings', 'should be recorded as AEs.', '7.1.2.3 Vital Signs', 'Vital signs include temperature, pulse, respiratory rate, weight, and blood pressure. The', 'investigator or qualified designee will take vital signs at screening, prior to the administration', 'of each dose of trial treatment, during the follow-up phase, and at other visits as specified in', 'the Trial Flow Chart (Section 6.0). Height will be measured at Visit 1 only.', '7.1.2.4 12-Lead Electrocardiogram', 'A standard 12-lead electrocardiogram will be performed using local standard procedures', 'once at screening. Clinically significant abnormal findings should be recorded as medical', 'history.', '7.1.2.5 Eastern Cooperative Oncology Group Performance Status', 'The investigator or qualified designee will assess ECOG status (see Section 12.3) at', 'screening, prior to each cycle of trial treatment and during the Follow-up period as specified', 'in the Trial Flow Chart (Section 6).', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '75', 'Protocol/Amendment No.: 604-09', '7.1.2.6 Prophylactic Cranial Irradiation', 'Subjects in either arm who achieve CR or PR after Cycle 4 may be offered PCI at the', 'discretion of the treating investigator. Imaging of the brain must occur after the completion', 'of 4 cycles of trial treatment, just prior to PCI.', 'Subjects selected to receive PCI may receive up to 25 Gy in 10 fractions (or the biologic', 'equivalent), as tolerated by the subject. If given, PCI must begin within 6 weeks (preferably', 'within 2 to 4 weeks) after the last dose of study medication in Cycle 4. Study medication may', 'continue during PCI; however, if it is necessary to suspend study treatment, dosing must be', 'restarted no later than 2 weeks after completion of PCI. Steroids can be administered, as', 'required, during and after PCI.', '7.1.2.7 Tumor Imaging and Assessment of Disease', 'The process for image collection and transmission to BICR can be found in the Site Imaging', 'Manual. The same imaging technique regarding modality and use of contrast should be used', 'consistently throughout the trial. Imaging schedule should follow calendar days and should', 'not be adjusted for cycle delays.', 'Screening (baseline) imaging:', 'CT with IV and oral contrast (preferred) of the chest, abdomen and pelvis for all', 'subjects, or non-contrast CT of the chest and magnetic resonance imaging (MRI) of', 'the abdomen and pelvis with IV gadolinium for subjects in whom iodinated contrast', 'is contraindicated', 'MRI (strongly preferred) or CT with contrast (when MRI is medically', 'contraindicated) of the brain for all subjects', 'Nuclear medicine bone scan for bone lesions', 'Post baseline imaging:', 'CT or MRI of the chest, abdomen and pelvis, consistent with the method used at', 'baseline', 'Imaging of the brain, consistent with the method used at baseline:', 'At all post-baseline visits for subjects with baseline brain metastases', 'For subjects who will undergo PCI, should be performed prior to PCI', 'If clinically indicated', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}